NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, announced that its broad-spectrum antiviral candidate NV-387 warrants evaluation as a potential treatment for the rapidly expanding Bundibugyo strain Ebola outbreak in Africa. The company noted the absence of approved vaccines or therapies specifically targeting this virus strain, underscoring the urgent need for effective interventions.
NV-387 employs a host-targeted antiviral mechanism, which could offer significant advantages in outbreak settings where treatment delivery and healthcare worker safety are critical. Additionally, its oral formulation simplifies administration compared to injectable therapies, potentially improving patient access and reducing logistical challenges in resource-limited regions.
The company is already preparing NV-387 for a Phase II clinical trial in the Democratic Republic of Congo for mpox (formerly monkeypox). This ongoing development could support near-term regional availability if the drug proves effective against Ebola. The overlap in viral mechanisms and the broad-spectrum nature of NV-387 suggest it may be active against multiple orthopoxviruses and filoviruses, including the Bundibugyo strain.
NanoViricides’ technology platform is based on proprietary nanomaterials designed to target viruses directly. The company holds exclusive licenses from TheraCour Pharma, Inc. for developing antiviral drugs using this technology. NV-387 is the lead candidate, initially developed for respiratory viruses such as RSV, COVID-19, and influenza, but its versatility has expanded its potential applications to include mpox and now Ebola.
The Bundibugyo Ebola outbreak has raised global health concerns due to its rapid spread and limited treatment options. Current Ebola vaccines and therapies, such as Ervebo and Inmazeb, are effective against the Zaire strain but have not been approved for the Bundibugyo strain. This gap highlights the potential significance of NV-387 as a broad-spectrum therapeutic.
Anish Khan, CEO of NanoViricides, stated, “We believe NV-387’s unique mechanism and oral formulation make it a strong candidate for outbreak scenarios. Our ongoing work in mpox could accelerate its availability in Africa, and we are actively seeking partnerships to evaluate its efficacy against Ebola.”
For more details, the full press release is available at https://ibn.fm/aSF5Z. Information about NanoViricides and its pipeline can be found at http://www.nanoviricides.com.
The company cautions that drug development is lengthy and capital-intensive, and there is no assurance that NV-387 will prove safe and effective in humans. However, the potential to address an unmet medical need in an outbreak context underscores the importance of this announcement.
